Showing 2781-2790 of 8596 results for "".
Diversity and Equity in Dermatology
https://practicaldermatology.com/topics/practice-management/diversity-and-equity-in-dermatology/23456/DermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketWishful Thinking: Looking to the Year Ahead
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/wishful-thinking-looking-to-the-year-ahead/23435/Cosmetic Surgery Forum faculty share resolutions for 2021.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-17/23343/Vitiligo: Oral and Topical JAKs Show Promise
https://practicaldermatology.com/topics/pigmentary-disorders/vitiligo-oral-and-topical-jaks-show-promise/23316/Early studies offer some hope for emerging therapies for repigmentation.6 Tools That Can Benefit Every Dermatology Provider
https://practicaldermatology.com/topics/practice-management/6-tools-that-can-benefit-every-dermatology-provider/23283/Whether you’ve never heard of it or simply forgot about it, each of these tools can improve patient care in the clinic.Your Comprehensive Guide to Energy-Based Devices
https://practicaldermatology.com/topics/practice-management/your-comprehensive-guide-to-energy-based-devices/23146/Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobA Review of Incident to Services
https://practicaldermatology.com/topics/practice-management/a-review-of-incident-to-services/20526/In order to ensure correct billing—and reimbursements—it is important to understand incident to policies.Lyme Disease Update
https://practicaldermatology.com/topics/general-topics/lyme-disease-update/20604/Exploring current thinking about Lyme Disease diagnosis and treatment.